Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point-Reference-Cited by-同舟云学术

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point

Published:2017-04-14 Issue:8 Volume:60 Page:3438-3450
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ward Richard A.¹^ORCID,Bethel Paul²,Cook Calum¹,Davies Emma¹,Debreczeni Judit E.¹,Fairley Gary¹,Feron Lyman¹,Flemington Vikki¹,Graham Mark A.²,Greenwood Ryan¹,Griffin Nicola³,Hanson Lyndsey³,Hopcroft Philip¹,Howard Tina D.³,Hudson Julian³,James Michael³,Jones Clifford D.³,Jones Christopher R.³,Lamont Scott¹,Lewis Richard²,Lindsay Nicola¹,Roberts Karen¹,Simpson Iain¹,St-Gallay Steve³,Swallow Steve²,Tang Jia⁴,Tonge Michael¹,Wang Zhenhua⁴,Zhai Baochang⁴

Affiliation:

1. IMED Oncology and Discovery Sciences, AstraZeneca, Darwin Building, and AstraZeneca, Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.

2. AstraZeneca, Charter Way, Macclesfield, SK10 2NA, U.K.

3. AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.

4. Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P.R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00267

Reference30 articles.

1. MAP kinase signalling pathways in cancer

2. Hallmarks of Cancer: The Next Generation